A Phase 2/3 interventional study of Molnupiravir and Placebo in Coronavirus Disease (COVID-19), sponsored by Merck Sharp & Dohme LLC. Completed at 173 sites in 23 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-28.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing molnupiravir in COVID-19 — 4 open to participants now, 4 under way, 2 of them phase 3. molnupiravir · COVID-19.
Among the 14 studies testing molnupiravir in COVID-19, this one is the 5th largest by enrollment, is one of 5 that started in 2020, is one of 3 in phase 2/3, and was the 3rd registered.
7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.
Browse COVID-19 studies →4 of the 14 studies testing molnupiravir in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Brazil and 21 more countries
Ages 18+
University of Oxford · Sites in Brazil, Laos, Nepal and 2 more countries
Ages 18–60
University of Liverpool · Sites in South Africa, United Kingdom
Ages 18+
University of Oxford · Sites in Belgium, Estonia, France and 13 more countries
Ages 0+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 8
First in 2020; this study’s year is marked. 5 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,735 is above the median of 102 across 4,366 interventional studies indexed under COVID-19.
Median enrollment 275 across the 14 interventional studies. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 14 have an industry lead sponsor. The 9 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
11 studies in COVID-19 by Merck & Co., Inc: 1 open now, 1 under way, 1 of them phase 3. Of 9 finished, 8 (89%) have results posted.
Among the 11 studies in COVID-19 by Merck & Co., Inc, this one is the 3rd largest by enrollment, is one of 7 that started in 2020, is one of 2 in phase 2/3, and was the 6th registered.
Merck & Co., Inc’s COVID-19 studies by the year they started, since 2020.
2 of the studies testing molnupiravir in COVID-19 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05041907University of OxfordFinding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) | 2027-01 |
| NCT04746183University of LiverpoolAGILE (Early Phase Platform Trial for COVID-19) | 2027-03-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies testing molnupiravir in COVID-19, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 11 in COVID-19:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the safety, tolerability and efficacy of molnupiravir (MK-4482) compared to placebo. The primary hypothesis is that molnupiravir is superior to placebo as assessed by the percentage of participants who are hospitalized and/or die through Day 29
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
200 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)
Drug: Molnupiravir
400 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)
Drug: Molnupiravir
800 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)
Drug: Molnupiravir
Placebo matching molnupiravir administered orally every 12 hours for 5 days (10 doses total)
Drug: Placebo
800 mg Molnupiravir (dose to be selected) administered orally every 12 hours for 5 days (10 doses total)
Drug: Molnupiravir
Placebo matching molnupiravir administered orally every 12 hours for 5 days (10 doses total)
Drug: Placebo
Molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
Also known as: MK-4482
Placebo matching molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
Percentage of Participants Who Were Hospitalized and/or Died Through Day 29 (Primary Pre-specified Analysis)
The percentage of participants who were hospitalized and/or died through Day 29 is presented. Hospitalization (all cause) is defined as at least 24 hours of acute care in a hospital or similar acute care facility. Death was due to any cause. Any participants with an unknown survival status at Day 29 were treated as failure. The analysis in Part 2 was based on all participants enrolled by the pre-specified futility/early efficacy analysis and was used for demonstration of superiority to placebo for the primary efficacy outcome measure.
Time frame: Up to 29 days
Number of Participants With an Adverse Event (AE)
The number of participants with at least 1 AE is presented. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to 318 days
Number of Participants Who Discontinued Study Intervention Due to an AE
The number of participants who discontinued study intervention due to an AE is presented. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to 5 days
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Cough
Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.
Time frame: Up to 29 days
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Sore Throat
Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.
Time frame: Up to 29 days
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Nasal Congestion
Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.
Time frame: Up to 29 days
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Rhinorrhea
Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.
Time frame: Up to 29 days
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Shortness of Breath or Difficulty Breathing
Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.
Time frame: Up to 29 days
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Muscles or Body Aches
Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.
Time frame: Up to 29 days
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Fatigue
Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.
Time frame: Up to 29 days
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Feeling Hot or Feverish
Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.
Time frame: Up to 29 days
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Chills
Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.
Time frame: Up to 29 days
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Headache
Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.
Time frame: Up to 29 days
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Nausea
Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.
Time frame: Up to 29 days
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Vomiting
Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.
Time frame: Up to 29 days
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Diarrhea
Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.
Time frame: Up to 29 days
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Loss of Taste
Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.
Time frame: Up to 29 days
Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Loss of Smell
Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.
Time frame: Up to 29 days
Time to Progression of Each Targeted COVID-19 Sign/Symptom - Cough
Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.
Time frame: Up to 29 days
Time to Progression of Each Targeted COVID-19 Sign/Symptom - Sore Throat
Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.
Time frame: Up to 29 days
Time to Progression of Each Targeted COVID-19 Sign/Symptom - Nasal Congestion
Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.
Time frame: Up to 29 days
Time to Progression of Each Targeted COVID-19 Sign/Symptom - Rhinorrhea
Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.
Time frame: Up to 29 days
Time to Progression of Each Targeted COVID-19 Sign/Symptom - Shortness of Breath or Difficulty Breathing
Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.
Time frame: Up to 29 days
Time to Progression of Each Targeted COVID-19 Sign/Symptom - Muscle or Body Aches
Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.
Time frame: Up to 29 days
Time to Progression of Each Targeted COVID-19 Sign/Symptom - Fatigue
Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.
Time frame: Up to 29 days
Time to Progression of Each Targeted COVID-19 Sign/Symptom - Feeling Hot or Feverish
Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.
Time frame: Up to 29 days
Time to Progression of Each Targeted COVID-19 Sign/Symptom - Chills
Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.
Time frame: Up to 29 days
Time to Progression of Each Targeted COVID-19 Sign/Symptom - Headache
Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.
Time frame: Up to 29 days
Time to Progression of Each Targeted COVID-19 Sign/Symptom - Nausea
Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.
Time frame: Up to 29 days
Time to Progression of Each Targeted COVID-19 Sign/Symptom - Vomiting
Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.
Time frame: Up to 29 days
Time to Progression of Each Targeted COVID-19 Sign/Symptom - Diarrhea
Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.
Time frame: Up to 29 days
Time to Progression of Each Targeted COVID-19 Sign/Symptom - Loss of Taste
Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.
Time frame: Up to 29 days
Time to Progression of Each Targeted COVID-19 Sign/Symptom - Loss of Smell
Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.
Time frame: Up to 29 days
Number of Participants With Responses on WHO 11-point Ordinal Outcomes Score on a Scale on Day 3
The World Health Organization (WHO) outcome scale is an 11-point ordinal score that categorizes clinical progression. Score ranges from 0 ("uninfected") to 10 ("dead") with higher score indicating clinical progression. The number of participants at each score category is presented.
Time frame: Day 3
Number of Participants With Responses on WHO 11-point Ordinal Outcomes Score on a Scale on End of Treatment (EOT [Day 5])
The World Health Organization (WHO) outcome scale is an 11-point ordinal score that categorizes clinical progression. Score ranges from 0 ("uninfected") to 10 ("dead") with higher score indicating clinical progression. The number of participants at each score category is presented.
Time frame: EOT (Day 5)
Number of Participants With Responses on WHO 11-point Ordinal Outcomes Score on a Scale on Day 10
The World Health Organization (WHO) outcome scale is an 11-point ordinal score that categorizes clinical progression. Score ranges from 0 ("uninfected") to 10 ("dead") with higher score indicating clinical progression. The number of participants at each score category is presented.
Time frame: Day 10
Number of Participants With Responses on WHO 11-point Ordinal Outcomes Score on a Scale on Day 15
The World Health Organization (WHO) outcome scale is an 11-point ordinal score that categorizes clinical progression. Score ranges from 0 ("uninfected") to 10 ("dead") with higher score indicating clinical progression. The number of participants at each score category is presented.
Time frame: Day 15
Number of Participants With Responses on WHO 11-point Ordinal Outcomes Score on a Scale on Day 29
The World Health Organization (WHO) outcome scale is an 11-point ordinal score that categorizes clinical progression. Score ranges from 0 ("uninfected") to 10 ("dead") with higher score indicating clinical progression. The number of participants at each score category is presented.
Time frame: Day 29
Participants were enrolled at 123 study centers in 21 countries.
| Milestone | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Started | 75 | 77 | 76 | 74 | 716 | 717 |
| Treated | 74 | 77 | 74 | 74 | 710 | 701 |
| Completed | 71 | 74 | 71 | 69 | 675 | 663 |
| Not completed | 4 | 3 | 5 | 5 | 41 | 54 |
| Withdrew: Death | 0 | 0 | 0 | 1 | 3 | 14 |
| Withdrew: Lost to follow-up | 2 | 1 | 1 | 2 | 10 | 8 |
| Withdrew: Withdrawal by subject | 2 | 2 | 4 | 2 | 25 | 28 |
| Withdrew: Not recorded | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Randomized by mistake without study treatment | 0 | 0 | 0 | 0 | 3 | 2 |
The percentage of participants who were hospitalized and/or died through Day 29 is presented. Hospitalization (all cause) is defined as at least 24 hours of acute care in a hospital or similar acute care facility. Death was due to any cause. Any participants with an unknown survival status at Day 29 were treated as failure. The analysis in Part 2 was based on all participants enrolled by the pre-specified futility/early efficacy analysis and was used for demonstration of superiority to placebo for the primary efficacy outcome measure.
| Percentage of Participants | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Percentage of Participants Who Were Hospitalized and/or Died Through Day 29 (Primary Pre-specified Analysis) | 1.4 | 3.9 | 4.1 | 5.4 | 7.3 | 14.1 |
The number of participants with at least 1 AE is presented. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
| Participants | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Number of Participants With an Adverse Event (AE) | 29 | 24 | 29 | 28 | 230 | 239 |
The number of participants who discontinued study intervention due to an AE is presented. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
| Participants | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Number of Participants Who Discontinued Study Intervention Due to an AE | 0 | 0 | 3 | 1 | 10 | 20 |
Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.
| Days | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Cough | 7.0 (5.0 to 10.0) | 6.5 (4.0 to 10.0) | 8.0 (6.0 to 11.0) | 6.0 (4.0 to 7.0) | 10.0 (9.0 to 11.0) | 10.0 (8.0 to 11.0) |
Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.
| Days | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Sore Throat | 3.0 (2.0 to 4.0) | 3.0 (2.0 to 5.0) | 4.5 (3.0 to 8.0) | 5.0 (3.0 to 7.0) | 4.0 (4.0 to 5.0) | 5.0 (5.0 to 6.0) |
Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.
| Days | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Nasal Congestion | 4.0 (3.0 to 6.0) | 4.0 (3.0 to 7.0) | 8.0 (5.0 to 10.0) | 5.0 (4.0 to 6.0) | 5.0 (4.0 to 6.0) | 6.0 (5.0 to 7.0) |
Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.
| Days | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Rhinorrhea | 4.0 (2.0 to 6.0) | 8.0 (5.0 to 10.0) | 9.0 (5.0 to 21.0) | 5.0 (3.0 to 6.0) | 5.0 (4.0 to 6.0) | 5.0 (5.0 to 6.0) |
Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.
| Days | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Shortness of Breath or Difficulty Breathing | 7.0 (4.0 to 22.0) | 4.0 (3.0 to 6.0) | 9.0 (4.0 to 17.0) | 5.0 (4.0 to 12.0) | 6.0 (6.0 to 8.0) | 9.0 (6.0 to 10.0) |
Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.
| Days | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Muscles or Body Aches | 5.0 (3.0 to 7.0) | 4.0 (3.0 to 4.0) | 4.5 (3.0 to 15.0) | 4.0 (3.0 to 7.0) | 4.0 (4.0 to 5.0) | 5.0 (4.0 to 5.0) |
Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.
| Days | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Fatigue | 7.0 (4.0 to 11.0) | 5.0 (3.0 to 7.0) | 6.0 (4.0 to 11.0) | 6.0 (4.0 to 10.0) | 6.0 (6.0 to 7.0) | 7.0 (6.0 to 8.0) |
Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.
| Days | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Feeling Hot or Feverish | 4.0 (3.0 to 6.0) | 2.0 (2.0 to 3.0) | 4.0 (3.0 to 5.0) | 3.5 (2.0 to 4.0) | 3.0 (3.0 to 4.0) | 4.0 (3.0 to 4.0) |
Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.
| Days | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Chills | 2.0 (2.0 to 5.0) | 2.0 (2.0 to 4.0) | 3.0 (2.0 to 3.0) | 4.0 (2.0 to 5.0) | 3.0 (2.0 to 3.0) | NA (NA to NA) |
Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.
| Days | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Headache | 4.0 (3.0 to 6.0) | 4.0 (3.0 to 7.0) | 4.0 (3.0 to 10.0) | 6.0 (3.0 to 10.0) | 5.0 (4.0 to 5.0) | 5.0 (5.0 to 6.0) |
Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.
| Days | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Nausea | 5.0 (2.0 to 8.0) | 3.0 (2.0 to 4.0) | 6.0 (2.0 to 9.0) | 5.0 (2.0 to 9.0) | 4.0 (3.0 to 5.0) | 4.0 (3.0 to 4.0) |
Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.
| Days | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Vomiting | 4.0 (2.0 to 6.0) | 8.0 (2.0 to 14.0) | 5.0 (2.0 to 8.0) | 2.0 (2.0 to 4.0) | 3.0 (2.0 to 4.0) | NA (NA to NA) |
Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.
| Days | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Diarrhea | 6.0 (2.0 to 13.0) | 4.0 (2.0 to 4.0) | 3.0 (2.0 to 6.0) | 2.0 (2.0 to 3.0) | 3.0 (3.0 to 4.0) | 3.0 (3.0 to 4.0) |
Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.
| Days | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Loss of Taste | 6.0 (4.0 to 9.0) | 6.0 (4.0 to 11.0) | 10.0 (4.0 to 19.0) | 9.0 (5.0 to 16.0) | 9.0 (8.0 to 10.0) | 10.0 (8.0 to 12.0) |
Time to sustained resolution or improvement of the targeted sign/symptom was defined as the number of days from randomization to the first of three consecutive days when resolution or improvement of the targeted sign/symptom was demonstrated and did not worsen by Day 29. The median number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement is presented. Per protocol, participants without the targeted sign/symptom reported at randomization were not included in the analysis.
| Days | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Time to Sustained Resolution or Improvement of Each Targeted COVID-19 Sign/Symptom - Loss of Smell | 7.0 (6.0 to 9.0) | 10.0 (6.0 to 18.0) | 12.0 (6.0 to 19.0) | 12.0 (7.0 to 16.0) | 10.0 (9.0 to 11.0) | 11.0 (9.0 to 14.0) |
Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.
| Days | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Time to Progression of Each Targeted COVID-19 Sign/Symptom - Cough | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.
| Days | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Time to Progression of Each Targeted COVID-19 Sign/Symptom - Sore Throat | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.
| Days | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Time to Progression of Each Targeted COVID-19 Sign/Symptom - Nasal Congestion | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.
| Days | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Time to Progression of Each Targeted COVID-19 Sign/Symptom - Rhinorrhea | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.
| Days | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Time to Progression of Each Targeted COVID-19 Sign/Symptom - Shortness of Breath or Difficulty Breathing | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.
| Days | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Time to Progression of Each Targeted COVID-19 Sign/Symptom - Muscle or Body Aches | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.
| Days | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Time to Progression of Each Targeted COVID-19 Sign/Symptom - Fatigue | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.
| Days | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Time to Progression of Each Targeted COVID-19 Sign/Symptom - Feeling Hot or Feverish | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.
| Days | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Time to Progression of Each Targeted COVID-19 Sign/Symptom - Chills | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.
| Days | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Time to Progression of Each Targeted COVID-19 Sign/Symptom - Headache | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.
| Days | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Time to Progression of Each Targeted COVID-19 Sign/Symptom - Nausea | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.
| Days | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Time to Progression of Each Targeted COVID-19 Sign/Symptom - Vomiting | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.
| Days | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Time to Progression of Each Targeted COVID-19 Sign/Symptom - Diarrhea | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.
| Days | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Time to Progression of Each Targeted COVID-19 Sign/Symptom - Loss of Taste | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Time to progression of the targeted sign/symptom was defined as the number of days from randomization to the first of two consecutive days when the targeted sign/symptom was worsened. The median number of days from randomization to the first day on or before study Day 29 for progression/worsening is presented. Per protocol, participants with symptoms reported at randomization as severe for the targeted sign/symptom were not included in the analysis.
| Days | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Time to Progression of Each Targeted COVID-19 Sign/Symptom - Loss of Smell | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
The World Health Organization (WHO) outcome scale is an 11-point ordinal score that categorizes clinical progression. Score ranges from 0 ("uninfected") to 10 ("dead") with higher score indicating clinical progression. The number of participants at each score category is presented.
| Participants | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| 0 | 2 | 0 | 0 | 1 | 2 | 3 |
| 1 | 2 | 2 | 1 | 1 | 11 | 13 |
| 2 | 68 | 72 | 66 | 66 | 655 | 640 |
| 3 | 0 | 0 | 2 | 2 | 13 | 10 |
| 4 | 0 | 1 | 3 | 0 | 7 | 4 |
| 5 | 0 | 0 | 1 | 0 | 4 | 13 |
| 6 | 0 | 0 | 0 | 0 | 3 | 1 |
| 7 | 0 | 0 | 0 | 0 | 0 | 0 |
| 8 | 0 | 0 | 0 | 0 | 0 | 0 |
| 9 | 0 | 0 | 0 | 0 | 0 | 0 |
| 10 | 0 | 0 | 0 | 0 | 0 | 0 |
The World Health Organization (WHO) outcome scale is an 11-point ordinal score that categorizes clinical progression. Score ranges from 0 ("uninfected") to 10 ("dead") with higher score indicating clinical progression. The number of participants at each score category is presented.
| Participants | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| 0 | 3 | 0 | 2 | 1 | 11 | 10 |
| 1 | 9 | 5 | 3 | 3 | 36 | 34 |
| 2 | 58 | 69 | 63 | 65 | 613 | 593 |
| 3 | 0 | 0 | 0 | 1 | 14 | 9 |
| 4 | 0 | 0 | 1 | 0 | 10 | 13 |
| 5 | 0 | 1 | 1 | 0 | 7 | 21 |
| 6 | 0 | 0 | 0 | 0 | 5 | 2 |
| 7 | 0 | 0 | 0 | 0 | 0 | 1 |
| 8 | 0 | 0 | 1 | 0 | 0 | 1 |
| 9 | 0 | 0 | 0 | 0 | 1 | 0 |
| 10 | 0 | 0 | 0 | 0 | 0 | 0 |
The World Health Organization (WHO) outcome scale is an 11-point ordinal score that categorizes clinical progression. Score ranges from 0 ("uninfected") to 10 ("dead") with higher score indicating clinical progression. The number of participants at each score category is presented.
| Participants | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| 0 | 9 | 11 | 3 | 4 | 40 | 32 |
| 1 | 15 | 8 | 7 | 13 | 68 | 81 |
| 2 | 45 | 52 | 56 | 49 | 519 | 493 |
| 3 | 0 | 0 | 0 | 0 | 12 | 6 |
| 4 | 0 | 0 | 1 | 2 | 16 | 23 |
| 5 | 1 | 1 | 1 | 1 | 11 | 21 |
| 6 | 0 | 1 | 0 | 0 | 4 | 11 |
| 7 | 0 | 0 | 0 | 0 | 1 | 2 |
| 8 | 0 | 0 | 1 | 0 | 2 | 3 |
| 9 | 0 | 0 | 0 | 0 | 0 | 1 |
| 10 | 0 | 0 | 0 | 0 | 0 | 0 |
The World Health Organization (WHO) outcome scale is an 11-point ordinal score that categorizes clinical progression. Score ranges from 0 ("uninfected") to 10 ("dead") with higher score indicating clinical progression. The number of participants at each score category is presented.
| Participants | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| 0 | 20 | 21 | 13 | 11 | 102 | 94 |
| 1 | 15 | 8 | 9 | 17 | 110 | 92 |
| 2 | 36 | 43 | 45 | 39 | 433 | 427 |
| 3 | 0 | 0 | 0 | 0 | 5 | 6 |
| 4 | 1 | 0 | 1 | 2 | 11 | 21 |
| 5 | 0 | 0 | 1 | 0 | 4 | 12 |
| 6 | 0 | 1 | 0 | 0 | 1 | 6 |
| 7 | 0 | 0 | 0 | 0 | 1 | 2 |
| 8 | 0 | 0 | 1 | 0 | 2 | 2 |
| 9 | 0 | 0 | 0 | 0 | 0 | 0 |
| 10 | 0 | 0 | 0 | 0 | 0 | 5 |
The World Health Organization (WHO) outcome scale is an 11-point ordinal score that categorizes clinical progression. Score ranges from 0 ("uninfected") to 10 ("dead") with higher score indicating clinical progression. The number of participants at each score category is presented.
| Participants | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| 0 | 35 | 40 | 39 | 36 | 312 | 314 |
| 1 | 14 | 13 | 10 | 16 | 126 | 115 |
| 2 | 19 | 19 | 15 | 14 | 197 | 198 |
| 3 | 0 | 0 | 0 | 0 | 1 | 1 |
| 4 | 0 | 0 | 2 | 1 | 4 | 10 |
| 5 | 0 | 0 | 0 | 0 | 2 | 2 |
| 6 | 0 | 0 | 0 | 0 | 0 | 0 |
| 7 | 0 | 0 | 0 | 0 | 0 | 1 |
| 8 | 0 | 0 | 0 | 0 | 2 | 0 |
| 9 | 0 | 0 | 0 | 0 | 0 | 0 |
| 10 | 0 | 0 | 0 | 0 | 1 | 9 |
The percentage of participants who were hospitalized and/or died through Day 29 is presented. Hospitalization (all cause) is defined as at least 24 hours of acute care in a hospital or similar acute care facility. Death was due to any cause. Any participants with an unknown survival status at Day 29 were treated as failure. This analysis was based on all randomized participants in Part 2 who received at least one dose of study treatment, were not hospitalized prior to the administration of the first dose of study intervention, and had reached Day 29 post treatment.
| Percentage of Participants | Part 2: Molnupiravir 800 mg | Part 2: Placebo |
|---|---|---|
| Percentage of Participants Who Were Hospitalized and/or Died Through Day 29 | 6.8 | 9.7 |
Collected over Up to 318 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: MK-4482 200 mg | 0/75 (0%) | 1/74 (1.4%) | 6/74 (8.1%) |
| Part 1: MK-4482 400 mg | 0/77 (0%) | 3/77 (3.9%) | 4/77 (5.2%) |
| Part 1: MK-4482 800 mg | 0/76 (0%) | 4/74 (5.4%) | 5/74 (6.8%) |
| Part 1: Placebo | 1/74 (1.4%) | 5/74 (6.8%) | 9/74 (12.2%) |
| Part 2: MK-4482 800 mg | 4/716 (0.6%) | 51/710 (7.2%) | 38/710 (5.4%) |
| Part 2: Placebo | 16/717 (2.2%) | 67/701 (9.6%) | 38/701 (5.4%) |
| Event | Part 1: MK-4482 200 mg | Part 1: MK-4482 400 mg | Part 1: MK-4482 800 mg | Part 1: Placebo | Part 2: MK-4482 800 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 0/74 | 1/77 | 2/74 | 1/74 | 37/710 | 53/701 |
| COVID-19 pneumoniaInfections and infestations | 1/74 | 2/77 | 2/74 | 2/74 | 29/710 | 43/701 |
| PneumoniaInfections and infestations | 0/74 | 0/77 | 1/74 | 0/74 | 2/710 | 0/701 |
| Diabetic metabolic decompensationMetabolism and nutrition disorders | 0/74 | 0/77 | 0/74 | 1/74 | 0/710 | 1/701 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/74 | 1/77 | 0/74 | 1/74 | 1/710 | 1/701 |
| Peripheral vascular disorderVascular disorders | 0/74 | 0/77 | 0/74 | 1/74 | 0/710 | 0/701 |
| Thrombosis mesenteric vesselGastrointestinal disorders | 0/74 | 0/77 | 0/74 | 1/74 | 0/710 | 0/701 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/74 | 0/77 | 0/74 | 0/74 | 6/710 | 9/701 |
| Pneumonia bacterialInfections and infestations | 0/74 | 0/77 | 0/74 | 0/74 | 3/710 | 2/701 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/74 | 0/77 | 0/74 | 0/74 | 0/710 | 2/701 |
| Event | Part 1: MK-4482 200 mg | Part 1: MK-4482 400 mg | Part 1: MK-4482 800 mg | Part 1: Placebo | Part 2: MK-4482 800 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 3/74 | 2/77 | 3/74 | 5/74 | 23/710 | 17/701 |
| DiarrhoeaGastrointestinal disorders | 3/74 | 2/77 | 2/74 | 4/74 | 16/710 | 21/701 |
| Age, Continuous(years) | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo | Total |
|---|---|---|---|---|---|---|---|
| Mean | 49.5 ± 14.6 | 49.2 ± 14.2 | 51.0 ± 15.8 | 47.3 ± 15.2 | 44.4 ± 14.6 | 45.3 ± 15.0 | 45.6 ± 14.9 |
| Sex: Female, Male(Participants) | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo | Total |
|---|---|---|---|---|---|---|---|
| Female | 40 | 32 | 41 | 30 | 384 | 351 | 878 |
| Male | 35 | 45 | 35 | 44 | 332 | 366 | 857 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 29 | 30 | 23 | 33 | 355 | 356 | 826 |
| Not Hispanic or Latino | 46 | 46 | 51 | 39 | 355 | 358 | 895 |
| Unknown or Not Reported | 0 | 1 | 2 | 2 | 6 | 3 | 14 |
| Race (NIH/OMB)(Participants) | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 3 | 1 | 2 | 5 | 60 | 44 | 115 |
| Asian | 0 | 1 | 0 | 0 | 26 | 23 | 50 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 5 | 8 | 6 | 3 | 40 | 35 | 97 |
| White | 54 | 52 | 58 | 52 | 400 | 413 | 1029 |
| More than one race | 13 | 15 | 10 | 13 | 190 | 202 | 443 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Time from Symptom Onset to Randomization (Part 1)(Participants) | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo | Total |
|---|---|---|---|---|---|---|---|
| ≤5 Days | 51 | 52 | 52 | 50 | — | — | 205 |
| >5 Days | 24 | 25 | 24 | 24 | — | — | 97 |
| At Increased Risk of Severe Illness from Coronavirus Disease (COVID-19) (Part 1)(Participants) | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo | Total |
|---|---|---|---|---|---|---|---|
| Yes | 56 | 58 | 57 | 56 | — | — | 227 |
| No | 19 | 19 | 19 | 18 | — | — | 75 |
| Time from Symptom Onset to Randomization (Part 2)(Participants) | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo | Part 2: Molnupiravir 800 mg | Part 2: Placebo | Total |
|---|---|---|---|---|---|---|---|
| ≤ 3 days | — | — | — | — | 342 | 342 | 684 |
| > 3 days | — | — | — | — | 374 | 375 | 749 |
Showing the first 100 of 173 sites across 23 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Oct 2020 to primary completion in May 2022, 18 months.
Results were first posted in Jun 2023, 1 year 1 month after primary completion.
Of 73 industry-sponsored phase 2/3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 18 months is above that.
Counting every sponsor, half of 168 studies reached it within 11 months; a quarter within 5 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Molnupiravir